WuXi Biologics has entered into a Letter of Intent with an unnamed vaccine company to form a strategic partnership calling for WuXi Vaccines to build a dedicated manufacturing facility that will supply the partner’s vaccines for global markets. WuXi Vaccines, a JV formed by WuXi Biologics and Shanghai-based Hile Bio-Technology, estimates the value of the 20-year manufacturing contract will be over $3 billion. WuXi Vaccines expects its CDMO model will enable companies to develop and manufacture vaccines globally.
Source: China Biotoday
